SG10201912407YA - Nanoliposomal irinotecan for use in treating small cell lung cancer - Google Patents
Nanoliposomal irinotecan for use in treating small cell lung cancerInfo
- Publication number
- SG10201912407YA SG10201912407YA SG10201912407YA SG10201912407YA SG10201912407YA SG 10201912407Y A SG10201912407Y A SG 10201912407YA SG 10201912407Y A SG10201912407Y A SG 10201912407YA SG 10201912407Y A SG10201912407Y A SG 10201912407YA SG 10201912407Y A SG10201912407Y A SG 10201912407YA
- Authority
- SG
- Singapore
- Prior art keywords
- lung cancer
- small cell
- cell lung
- treating small
- nanoliposomal irinotecan
- Prior art date
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 208000000587 small cell lung carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US201762474661P | 2017-03-22 | 2017-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912407YA true SG10201912407YA (en) | 2020-02-27 |
Family
ID=59258274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809788VA SG11201809788VA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG10201912407YA SG10201912407YA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809788VA SG11201809788VA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (enExample) |
| EP (1) | EP3458059A1 (enExample) |
| JP (3) | JP2019516693A (enExample) |
| KR (1) | KR20190009319A (enExample) |
| CN (1) | CN109640995A (enExample) |
| AU (1) | AU2017267449A1 (enExample) |
| BR (1) | BR112018072988A2 (enExample) |
| CA (1) | CA3023743A1 (enExample) |
| IL (1) | IL262656A (enExample) |
| MA (1) | MA45046A (enExample) |
| MX (1) | MX394766B (enExample) |
| PH (1) | PH12018502422A1 (enExample) |
| SG (2) | SG11201809788VA (enExample) |
| TW (1) | TWI791437B (enExample) |
| UA (1) | UA125646C2 (enExample) |
| WO (1) | WO2017199093A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| JP2018528185A (ja) | 2015-08-21 | 2018-09-27 | イプセン バイオファーム リミティド | リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法 |
| SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
| KR20190077441A (ko) | 2016-11-02 | 2019-07-03 | 입센 바이오팜 리미티드 | 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2967961T3 (es) * | 2004-05-03 | 2024-05-06 | Ipsen Biopharm Ltd | Liposomas útiles en la administración de fármacos |
| EP2187869B1 (en) * | 2007-08-17 | 2015-10-14 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en not_active Ceased
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Ceased
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 MX MX2018013873A patent/MX394766B/es unknown
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI791437B (zh) | 2023-02-11 |
| AU2017267449A1 (en) | 2018-11-15 |
| TW201740946A (zh) | 2017-12-01 |
| MX2018013873A (es) | 2019-02-14 |
| JP2020117548A (ja) | 2020-08-06 |
| SG11201809788VA (en) | 2018-12-28 |
| US20230000858A1 (en) | 2023-01-05 |
| PH12018502422A1 (en) | 2019-03-11 |
| IL262656A (en) | 2018-12-31 |
| BR112018072988A2 (pt) | 2019-04-09 |
| MA45046A (fr) | 2019-03-27 |
| EP3458059A1 (en) | 2019-03-27 |
| CA3023743A1 (en) | 2017-11-23 |
| UA125646C2 (uk) | 2022-05-11 |
| CN109640995A (zh) | 2019-04-16 |
| JP2019516693A (ja) | 2019-06-20 |
| MX394766B (es) | 2025-03-24 |
| JP2022010295A (ja) | 2022-01-14 |
| KR20190009319A (ko) | 2019-01-28 |
| WO2017199093A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| IL272724B (en) | Gemcitabine drug inhibitors | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL248528A0 (en) | Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer | |
| IL251630A0 (en) | Combined therapy for use in cancer treatment | |
| IL262656A (en) | Nanoliposomal irinotecan for use in the treatment of small cell lung cancer | |
| IL251905A0 (en) | Epilimod for use in the treatment of kidney cancer | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
| IL251903B (en) | Epilimod for use in the treatment of colon cancer | |
| GB201420533D0 (en) | Use of Nanomaterials in treating cancer | |
| IL255079A0 (en) | Methods of treating lung cancer | |
| EP3736275C0 (en) | PRODRUGS OF OXABICYCLOHEPTANE FOR USE IN THE TREATMENT OF CANCER | |
| IL262143A (en) | Improvements in cancer treatment | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
| PL3518911T3 (pl) | Rad1901 do zastosowania w leczeniu nowotworu jajnika | |
| HK40003841A (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| HK1259160A1 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| GB201510764D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| GB201411111D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| HK1237824A1 (en) | Combination therapy for use in cancer therapy | |
| ZA201403006B (en) | Composition for use in treatment of cancer | |
| GB201414904D0 (en) | Materials and methods for treating cancer |